Novartis's Kisqali Demonstrates a 28.5% Decrease in Recurrence Risk in Early Breast Cancer Patients
Sep 17, 2024
Novartis Invest Information
Positive Topline Results for Novartis' Leqvio® in Lowering LDL-C in Low-to-Moderate ASCVD Risk Patients
Aug 28, 2024
Novartis Phase III Trial Shows Atrasentan Promising for IgA Nephropathy Treatment
May 26, 2024
Novartis Scemblix® Outperforms Traditional TKIs in Phase III CML Trial
Jan 8, 2024
Novartis NVS Receives 'Strong-Buy' Rating from StockNews.com Analysts
Nov 28, 2023